Boston Scientific (BSX) vs Medline (MDLN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Boston Scientific is the larger company by market cap ($60.26 billion vs $47.70 billion), about 1.3 times the size. On valuation, Boston Scientific trades at a lower forward P/E (12.3x vs 22.5x for Medline). Boston Scientific converts more of its revenue into profit, with a net margin of 14.4% versus 4.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BSX | MDLN |
|---|---|---|
| Share price | $41.58 | $35.45 |
| Market cap | $60.26B | $47.70B |
| 1-day change | -1.45% | -0.28% |
| YTD return | -56.39% | -15.60% |
| 1-year return | -56.64% | — |
| 5-year return | -4.19% | — |
| P/E ratio (TTM) | 16.83 | 88.63 |
| Forward P/E | 12.29 | 22.48 |
| EPS (TTM) | $2.47 | $0.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $20.07B | $28.43B |
| Revenue growth (YoY) | +19.87% | — |
| Net income (latest FY) | $2.89B | $1.16B |
| Gross margin | 69.01% | 26.44% |
| Operating margin | 18.00% | 7.78% |
| Net margin | 14.41% | 4.08% |
| 52-week high | $105.65 | $50.88 |
| 52-week low | $41.50 | $31.49 |
| Distance from 52-week high | -60.64% | -30.32% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +44.06% | +25.53% |
| Average volume | 19.67M | 7.61M |
| Shares outstanding | 1.45B | 877.35M |
| Employees | 59,000 | 45,000 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Medline trades at a higher earnings multiple (88.6x vs 16.8x trailing P/E).
- Boston Scientific is more profitable, keeping 14.4 cents of every revenue dollar as net income versus 4.1 cents for Medline.
About Boston Scientific
BSX stock →Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular.
Health Care · Medical/Dental Instruments · 59,000 employees
About Medline
MDLN stock →Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally.
Health Care · Medical/Dental Instruments · 45,000 employees
BSX vs MDLN FAQ
Which is bigger, Boston Scientific or Medline?
Boston Scientific (BSX) is larger, with a market capitalization of $60.26B compared with $47.70B for Medline (MDLN).
Which has the lower P/E ratio, BSX or MDLN?
BSX has the lower trailing P/E at 16.8, versus 88.6 for MDLN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Boston Scientific and Medline in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.